DLBCL and 24-month EFS

Patients with diffuse large B-cell lymphoma (DLBCL) who achieve event-free survival at 24 months also have overall survival that is equivalent to that of the age- and sex-matched general population.

In this study, patients (n = 767) with newly diagnosed DLBCL treated with immunochemotherapy were prospectively enrolled. At a median follow-up of 60 months, 299 patients had an event and 210 patients had died. A similar result was seen in 820 patients from the Groupe d’Étude des Lymphomes de l’Adulte (GELA) study. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.